IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.

Highlights ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Equities

1541

CNE100006624

Market Closed - Hong Kong S.E. Other stock markets 04:08:07 2024-06-05 am EDT			5-day change	1st Jan Change
14.66 ^HKD	+0.14%		+1.24%	-50.97%

Jun. 03	ImmuneOnco Biopharmaceuticals Gets China's Phase 3 Trial Approval for Leukemia Drug	MT
May. 30	ImmuneOnco Completes Filing with China Regulator for Conversion of H Shares	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ImmuneOnco Completes Filing with China Regulator for Conversion of H Shares	May. 30	MT
Immuneonco Biopharmaceuticals Inc. Receives Approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China for A Randomized, Double-Blind, Controlled Phase III Clinical Trial of MM01 (Timdarpacept) in Combination with Azacitidine for the First-Line Treatment of Higher-Risk Myelodysplastic Syndrome (HR MDS)	May. 17	CI
ImmuneOnco Obtains Chinese Nod for Phase III Trials of Anti-Cancer Medication	Apr. 17	MT
ImmuneOnco Biopharmaceuticals Inc. Receives Approval from the National Medical Products Administration of the People's Republic of China for the Protocol of the Phase Iii Clinical Trial of IMM01	Apr. 17	CI
Immuneonco Biopharmaceuticals' 2023 Loss Narrows as Other Income Increases	Mar. 26	MT
ImmuneOnco Biopharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
ImmuneOnco Biopharmaceuticals Inc. Announces First Patient Dosed in the Phase II Clinical Trial of IMM2510 for the Treatment of Refractory or Relapsed Alveolar Soft Part Sarcoma	Nov. 19	CI
ImmuneOnco Biopharmaceuticals Gets US FDA's Orphan-Drug Designation for Leukemia Drug Combination	Nov. 09	MT
ImmuneOnco Biopharmaceuticals Gets Nod to Trial Cancer Drug	Nov. 07	MT
ImmuneOnco Biopharmaceuticals Inc. Receives an Investigational New Drug Approval from the National Medical Products Administration of the People's Republic of China	Nov. 07	CI
ImmuneOnco Biopharmaceuticals Inc. Obtains an Investigational New Drug Approval for IMM47 for the Treatment of Solid Tumors from the National Medical Products Administration of the People's Republic of China	23-10-16	CI
Immuneonco Biopharmaceuticals Inc. Provides Updates on the Clinical Trial of Imm47	23-09-27	CI
ImmuneOnco Biopharmaceuticals Inc. Provides Updates on the Clinical Trials of IMM2510 and IMM27M	23-09-11	CI
ImmuneOnco Biopharmaceuticals Inc. has completed an IPO in the amount of HKD 318.93792 million.	23-09-04	CI
ImmuneOnco Biopharmaceuticals Raises HK$234.5 Million in Hong Kong IPO	23-09-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer